Australia's largest stock trading and investment forum Australia's #1 stock forum

CHM

0.00%

1.4¢ chimeric therapeutics limited

Some sobering news from another clinical startup targeting solid...

First 102 Last

Share
Profile

Follow
CoppiBartali

234 Posts.

30

15/05/23

11:34

Post #: 67774821
Share

Originally posted by jlechte: ↑

After reading this thread i can say im happily more informed to many perspectives and despite what as an example Fourdollars says, its good thinking and feedback. polar opposite views are exactly that, but they educate us to risks on both sides of the equation, like Hoppers track record in getting to drugs to market - one could argue that it was too early for cancer drugs years ago for this to happen, but its certainly a performance consideration and perhaps a concern. These are low odds investments that have not been solved / with new tech so that does support Hoppers agenda.

Regarding the management committee and pay I agree with both sides of the arguments presented and would say a couple of things: The stock market standard playbook for small caps is to list, create a mirage for retail / small investors, throw out hope, then off the back of this fund raise arguably fund big salaries - this behaviour is pretty pervasive and sometimes its honorable but a lot of times its dodgy capitalism. However, you cannot sell a sophisticated to-be product without a top gun exec, who needs to walk into boardrooms like Amgen or BMY and convince them of the near impossible happening. There are always examples on both sides of this.

Im better off for both sides of the opinions and the nuanced discussion, we all just need to keep it civil and respect the differences! Thanks all

Expand

Some sobering news from another clinical startup targeting solid tumors:

https://finance.yahoo.com/news/bellicum-blcm-down-ending-development-154103532.html

As they say - if it were easy it would have been done by now

Last edited by CoppiBartali: 15/05/23

CHM Price at posting: 4.0¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

The market's shrugged at China's stimulus measures all year. Why is this one different?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

There are more pages in this discussion • 37 more messages in this thread...

First 102 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change 0.000(0.00%)		Mkt cap ! $12.67M

Open	High	Low	Value	Volume
1.5¢	1.5¢	1.4¢	$15.87K	1.103M

Buyers (Bids)

No.	Vol.	Price($)
2	1876837	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	96056	2

View Market Depth

No.	Vol.	Price($)
2	1876837	0.014
12	2424769	0.013
5	1066816	0.012
4	697817	0.011
4	485142	0.010

Price($)	Vol.	No.
0.015	76056	1
0.016	735854	3
0.017	647827	3
0.018	1788235	5
0.019	987804	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

CHM (ASX) Chart

Some sobering news from another clinical startup targeting solid...

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Some sobering news from another clinical startup targeting solid...

Top Stories

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News